Chambers Michael Andrew 4

What Happened
Michael Andrew Chambers, a director of Sarepta Therapeutics (SRPT), received an award of 16,875 restricted stock units (RSUs) reported on 2026-06-04 and filed 2026-06-05. The filing lists the transaction as an Award/Grant (code A); no per-share price or immediate cash value is reported because RSUs convert to shares only upon vesting.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely).
• Transaction type/code: Grant/Award (A).
• Securities granted: 16,875 RSUs. Price: N/A (RSUs, not an open-market trade).
• Shares owned after transaction: Not specified in the provided excerpt.
• Footnote: RSUs vest on the earlier of the one-year anniversary of the grant or the next annual meeting of stockholders that is at least 50 weeks after the prior meeting (per footnote F1).
• No tax withholding, sales, exercises, or 10b5-1 plan noted in the excerpt.

Context
RSUs represent the right to receive one share each upon vesting and are typically compensation for service, not an immediate purchase or sale. Such grants are routine for directors and executives and do not by themselves indicate buying or selling intent. For investors, outright purchases by insiders can be a stronger signal than compensation grants.